SEC Form 4 · accession 0001677036-26-000006
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin Robert Lind
Director
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001534120
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $18.48 | Jun 30, 2026 | A | 1,105 | A | — | Jun 30, 2036 | Common Stock | 1,105 | 1,105 | D |
Explanation of responses
- F1The options were granted on June 30, 2026, and are 100% vested.